2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.
Cenerimod flunks a mid-stage lupus study, so Idorsia moves to go straight into phase 3. What can possibly go wrong?
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Daridorexant can't reach the heights of its first pivotal study win, but a pooled analysis could still save it.